EVERSANA’s field sales representatives use a comprehensive approach to navigate the practice environment. With an influencer map highlighting key publishers and key opinion leaders (KOLs), they strategically manage relationships. Equipped with real-world data (RWD), triggers, and NPP Assets, they enhance engagement and decision-making. Their deep understanding of healthcare professionals’ (HCP) preferences allows for tailored, impactful interactions.

With extensive knowledge, our reps are well-prepared to navigate the dynamic healthcare landscape and achieve meaningful outcomes.

Medical Science Liaisons (MSLs) are crucial in the pharmaceutical commercialization of high-science therapies, bridging the gap between scientific knowledge and patient treatment.

EVERSANA integrates MSLs early in the prelaunch phase as part of the launch team, guiding them in implementing brand strategies. We focus on recruiting individuals with deep knowledge of therapeutic areas and disease states to enhance scientific share of voice (SSoV) and brand harmony.

EVERSANA works flexibly with companies of all sizes, from small biotech firms focused on the scientific development of a compound and putting in place a complete medical affairs infrastructure, to larger or midsize companies with established medical affairs departments; therefore, focusing solely helping implement the field medical portion.

By providing comprehensive education and combining clinical and business expertise, EVERSANA’s MSLs deliver significant benefits throughout a product’s lifecycle.

CNEs are advanced-degree healthcare professionals with extensive clinical experience, deployed to address gaps in product utilization, adherence or adoption. Depending on their role, many CNEs are additionally credentialed to provide scientific disease state data and compliant communications, enhancing patient outcomes. They are vital for manufacturers with complex therapies.

As patients increasingly require personalized and holistic care, CNEs support this need by raising awareness, promoting disease management best practices and offering additional support for therapies with complex dosing and administration.

EVERSANA is revolutionizing account management by connecting FRMs to offices and patients needing immediate support. Our model integrates patient services, a hub, FRMs and a specialty pharmacy under one roof, enabling real-time data interaction. Traditional models see up to 70% of pre-authorization submissions to the hub being inaccurate or incomplete, causing delays. Our FRMs can address pre-authorization issues as they arise, working closely with office staff to ensure accurate submissions.

Additionally, EVERSANA’s FRMs use ACTICS® eAccess, our exclusive eBV and ePA solution, to reduce patient wait times and treatment delays. With over 1,400 digital connections to payers and integration of both pharmacy benefit (PBM) and major medical (MM), coverage can be confirmed in minutes. FRMs also access automated business logic to apply co-pay offerings and assess patient assistance program (PAP) eligibility, empowering them to take the most effective actions.

EVERSANA is uniquely positioned to address current industry challenges and bring benefit to our partners in large pharma, biotech, pharma, small and emerging rare disease. We have assembled the tools that a NAM or brand team would need to have an efficient and effective conversation with a payer earlier and in a unified fashion.

By developing a strategy backed by data, analytics and modeling, EVERSANA provides our partners with a complete picture of success in the market access arena. In addition, our NAMs work with distributors and wholesalers, IDNG, POs, and all the parts of the puzzle that deliver the product to the end user